News: Portfolio 2007

Safeguard Scientifics Leads $8.7 Million Series B Financing For Cellumen, Inc.

The growth equity financing will support the commercialization of Cellumen's proprietary cellular systems biology technology, which offers a powerful approach to improving drug discovery, drug development and clinical trials

July 10, 2007: Wayne, PA, - Safeguard Scientifics, Inc. (NYSE: SFE), a holding company that builds value in growth-stage technology and life sciences companies, today announced an $8.7 million Series B financing for Cellumen, Inc., a cellular systems biology (CSB) company, of which Safeguard provided $6 million. Joining Safeguard in the financing for $2 million is PA Early Stage Partners, a venture capital fund that provides capital to early stage life sciences and technology companies primarily based in the Mid-Atlantic region. PA Early Stage provided Cellumen with its Series A financing back in 2005.